Cormorant Asset Management LP's Q3 2026 13F: 13 new positions, 3 exits

Form 13F-HR for the quarter ended Sep 30, 2026 · filed Nov 16, 2026 · 60 reported positions · accession 0001583977-26-000011

What changed this quarter

Cormorant Asset Management LP's changes in reported equity positions, Q3 2026
Activity Security Weight before Weight now Change Shares Shares %
New BLOSSOMHILL THERAPEUTICS INC (BLSM) — 4.5% +4.5 pts +3.61M sh new
Reduced PRAXIS PRECISION MEDICINES I (PRAX) 11.0% 9.8% −1.2 pts −140K sh −22%
New ELECTRA THERAPEUTICS INC (ETRA) — 2.5% +2.5 pts +3.37M sh new
New ATTOVIA THERAPEUTICS INC (ATTO) — 2.1% +2.1 pts +1.79M sh new
New LATIGO BIOTHERAPEUTICS INC (LTGO) — 2.0% +2.0 pts +1.82M sh new
New OPUS GENETICS INC (OCUP) — 1.8% +1.8 pts +5.5M sh new
Reduced EDGEWISE THERAPEUTICS INC (EWTX) 5.2% 5.1% −0.2 pts −650K sh −26%
Reduced ABIVAX SA (ABVX) 4.6% 2.8% −1.8 pts −250K sh −37%
New FREENOME INC (FRNM) — 1.5% +1.5 pts +1.43M sh new
Reduced DIANTHUS THERAPEUTICS INC (DNTH) 3.7% 3.0% −0.8 pts −250K sh −33%
Exited DAMORA THERAPEUTICS INC (GLTO) 1.3% — −1.3 pts −1M sh −100%
Reduced BRIDGEBIO PHARMA INC (BBIO) 2.1% 1.1% −1.0 pts −300K sh −55%
New ADARX PHARMACEUTICALS INC (ADRX) — 1.3% +1.3 pts +963K sh new
New DAMORA THERAPEUTICS INC (DMRA) — 1.1% +1.1 pts +800K sh new
New CUE BIOPHARMA INC (CUE) — 1.1% +1.1 pts +625K sh new
Reduced TANGO THERAPEUTICS INC (TNGX) 2.1% 1.2% −0.9 pts −600K sh −46%
Reduced BIOHAVEN LTD (BHVN) 2.0% 1.4% −0.6 pts −1.1M sh −42%
Reduced ERASCA INC (ERAS) 5.6% 4.9% −0.7 pts −1M sh −17%
Reduced ROIVANT SCIENCES LTD (ROIV) 0.9% 0.2% −0.6 pts −375K sh −79%
Reduced ORUKA THERAPEUTICS INC (ORKA) 2.6% 2.2% −0.4 pts −133K sh −25%
Reduced MBX BIOSCIENCES INC (MBX) 1.6% 1.5% −0.1 pts −175K sh −32%
Reduced NEWAMSTERDAM PHARMA COMPANY (NAMS) 0.9% 0.2% −0.7 pts −400K sh −80%
Reduced PHARVARIS N V (PHVS) 1.3% 1.0% −0.4 pts −300K sh −40%
New ACLARIS THERAPEUTICS INC (ACRS) — 0.6% +0.6 pts +1.75M sh new
Reduced ALUMIS INC (ALMS) 4.7% 1.0% −3.7 pts −1.21M sh −37%
Reduced SPYRE THERAPEUTICS INC (SYRE) 1.0% 0.7% −0.3 pts −100K sh −44%
Reduced ASCENDIS PHARMA A/S (ASND) 0.7% 0.2% −0.5 pts −35,000 sh −70%
Reduced RAPPORT THERAPEUTICS INC (RAPP) 5.7% 5.5% −0.1 pts −200K sh −8%
Reduced INSMED INC (INSM) 0.4% 0.2% −0.3 pts −55,000 sh −73%
New INHIBRX BIOSCIENCES INC (INBX) — 0.3% +0.3 pts +50,000 sh new
Reduced BRIGHT MINDS BIOSCIENCES INC (DRUG) 3.2% 2.7% −0.6 pts −100K sh −11%
Reduced DEFINIUM THERAPEUTICS INC (DFTX) 1.0% 0.7% −0.3 pts −125K sh −31%
New JADE BIOSCIENCES INC (JBIO) — 0.3% +0.3 pts +300K sh new
Reduced MOONLAKE IMMUNOTHERAPEUTICS (MLTX) 3.2% 2.2% −1.0 pts −350K sh −11%
Reduced EYEPOINT INC (EYPT) 5.1% 1.3% −3.9 pts −1.25M sh −18%
Reduced TARSUS PHARMACEUTICALS INC (TARS) 0.3% 0.3% −0.1 pts −50,000 sh −50%
Exited CRINETICS PHARMACEUTICALS IN (CRNX) 0.2% — −0.2 pts −125K sh −100%
Reduced OLEMA PHARMACEUTICALS INC (OLMA) 1.4% 1.0% −0.4 pts −400K sh −19%
Reduced ENLIVEN THERAPEUTICS INC (ELVN) 0.4% 0.2% −0.2 pts −75,000 sh −50%
Reduced ARCUTIS BIOTHERAPEUTICS INC (ARQT) 0.2% 0.1% −0.1 pts −125K sh −71%
Increased AMYLYX PHARMACEUTICALS INC (AMLX) 0.2% 0.6% +0.4 pts +100K sh +50%
Exited ALTIMMUNE INC (ALT) 0.2% — −0.2 pts −1.25M sh −100%
Reduced RESEARCH ALLIANCE CORP III (RACC) 0.2% 0.1% −0.1 pts −245K sh −66%
Reduced ARROWHEAD PHARMACEUTICALS IN (ARWR) 0.2% 0.1% −0.1 pts −35,000 sh −70%
Reduced COGENT BIOSCIENCES INC (COGT) 0.2% 0.1% −0.1 pts −70,000 sh −70%
Reduced VAXCYTE INC (PCVX) 0.1% 0.1% −0.1 pts −35,000 sh −70%
Reduced KAILERA THERAPEUTICS INC (KLRA) 0.6% 0.3% −0.3 pts −150K sh −27%
New BRAVEHEART BIO INC (BRVE) — 0.1% +0.1 pts +70,000 sh new
Reduced STRUCTURE THERAPEUTICS INC (GPCR) 0.2% 0.1% −0.1 pts −45,000 sh −60%
Reduced ODYSSEY THERAPEUTICS INC (ODTX) 0.2% 0.2% 0.0 pts −50,000 sh −29%

The 50 largest of 53 changes, by size of the trade. Full holdings for this quarter.

Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled

Top 10 positions — 54.8% of the equity book

Changes in the top 10 this quarter: BLSM entered · ANL entered · EYPT left · ALMS left

# Security Weight before Weight now
1 PARABILIS MEDICINES INC (PBLS) 6.5% 10.0%
2 PRAXIS PRECISION MEDICINES I (PRAX) 11.0% 9.8%
3 RAPPORT THERAPEUTICS INC (RAPP) 5.7% 5.5%
4 EDGEWISE THERAPEUTICS INC (EWTX) 5.2% 5.1%
5 BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) 7.0% 4.9%
6 ERASCA INC (ERAS) 5.6% 4.9%
7 BLOSSOMHILL THERAPEUTICS INC (BLSM) 0.0% 4.5% Entered the top 10
8 ADLAI NORTYE GROUP LTD (ANL) 2.3% 4.3% Entered the top 10
9 DIANTHUS THERAPEUTICS INC (DNTH) 3.7% 3.0%
10 ABIVAX SA (ABVX) 4.6% 2.8%
— EYEPOINT INC (EYPT) 5.1% 1.3% Left the top 10
— ALUMIS INC (ALMS) 4.7% 1.0% Left the top 10

Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).